Abstract
The main objectives of this symposium were to explore the challenges faced when treating patients with severe eosinophilic asthma, to evaluate the key clinical assessments that are available for early disease recognition, and to discuss the latest personalised treatment options that could shape future management strategies. Prof Ian Pavord opened the symposium by introducing uncontrolled severe asthma, focussing on the challenges and unmet needs of patients. Prof Buhl then delved into the basics of eosinophilic asthma from a molecular and physiological point of view, discussing the clinical relevance and characterisation of eosinophilic patients. Prof Costello focussed on the key clinical assessments (diagnosis, adherence, and phenotyping) and management of patients. Prof Castro summarised the latest evidence from studies of mepolizumab, benralizumab, reslizumab, anti-interleukin (IL)-4, and anti-IL-13 therapies, and how this relates to clinical practice.